A5056556114- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Peptidase Inhibition and Analysis
- Synthesis and Biological Evaluation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Reproductive System and Pregnancy
- Mesenchymal stem cell research
- Cancer Risks and Factors
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Pregnancy and Medication Impact
- Neutropenia and Cancer Infections
- Data Visualization and Analytics
- Cancer Mechanisms and Therapy
- Renal Transplantation Outcomes and Treatments
- Immunotherapy and Immune Responses
- Patient-Provider Communication in Healthcare
University Hospital Carl Gustav Carus
2016-2025
TU Dresden
2014-2024
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2015-2024
Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. To test chemotherapy before HSCT, aged between 18 and 75 years non-favourable-risk not first induction untreated relapse were randomly assigned 1:1 cytarabine (3 g/m2 intravenously, 1...
Measurable residual disease (MRD) evaluation may help to guide treatment duration in multiple myeloma (MM). Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of dynamics 1280 transplant-eligible and -ineligible patients from TOURMALINE-MM3 -MM4 randomized placebo-controlled phase 3 studies 2-year ixazomib status at randomization showed independent (median progression-free survival [PFS], 38.6 vs 15.6 months MRD- MRD+ patients; HR,...
Inflammation plays an important role in chimeric antigen receptor (CAR) T-cell therapy, especially the pathophysiology of cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS). Clonal hematopoiesis indetermined potential (CHIP) has also been associated with chronic inflammation. The relevance CHIP context CAR treatment is widely unknown. We evaluated prevalence CHIP, using a targeted deep sequencing approach, cohort patients relapsed/refractory (r/r)...
Abstract Objective This study evaluated the legibility, comprehension, and clinical usability of visual timelines for communicating cancer treatment paths. We examined how these aids enhance participants’ patients’ understanding their plans. Materials Methods The included 2 online surveys 1 in-person survey with hematology patients. involved 306 160 participants, respectively, while evaluation 30 patients (11 re-surveyed) 24 medical doctors. Participants were assessed on ability to...
Abstract For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly include triplet regimens based on proteasome inhibitors, immunomodulatory drugs anti-CD38 monoclonal antibodies since recently also CAR T cells. The importance of salvage (retransplantation, Re-AHCT) has significantly decreased in...
BACKGROUND The collection of hematopoietic stem cells from the peripheral blood healthy donors has been established as a highly efficient method. Nevertheless, some have moderate or poor chance harvest success with standard mobilization regimens. STUDY DESIGN AND METHODS We retrospectively reviewed data 7216 unrelated donors, who underwent granulocyte–colony‐stimulating factor and consecutive leukapheresis for allogeneic cell transplantation. tested different donor variables potential...
This study was conducted to characterize and compare peripheral blood stem cell grafts from healthy donors who underwent granulocyte colony-stimulating factor (G-CSF) mobilization subsequently received 1 dose of plerixafor after insufficient yields were achieved at the first apheresis. Aliquots 35 collected apheresis with G-CSF alone second additional administration. Samples freshly analyzed for cellular subsets by 8-color flow cytometry. Leukapheresis samples mobilized showed a significant...
7531 Background: MM eventually becomes refractory to current treatments, and new therapeutic options with convenient dosing improved safety are needed enhance patient (pt) adherence, access, outcomes. ABBV-383 is a distinctive next-generation BCMA x CD3 bispecific antibody composed of 2 high-affinity BCMA-binding domains, low-affinity CD3-binding domain designed reduce cytokine release syndrome (CRS) risk, silenced Fc tail for an extended half-life allowing dosing. monotherapy has shown...
Abstract We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 × 10 6 CD34 + cells/kg recipient body-weight (CD34+/kg RBW) after 1st apheresis. A single dose 240 µg/kg P was injected subcutaneously at p.m. on day Thirty-seven PBSC underwent study treatment. The median CD34+ count...
We performed a registry-based analysis of 311 AML patients treated with decitabine in standard care setting to assess response and survival data distinct focus on the impact TP53 mutation status. Median age was 73 years. 172 received first-line 139 r/r disease. The ORR (whole cohort) 30% median overall 4.7 months. First-line achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting OS 5.8 months 3.9 NGS based 180 patients. 20 (11%) harbored mutation. Response rates did not...
Abstract Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth in a contemporary cohort, we conducted national multicenter study using data from the German Transplant Registry, focusing on women aged 18 to 40 years who underwent alloHCT between 2003 2018. Of 2654 transplantation, 50...
Radioimmunotherapy (RIT) has the potential to reduce incidence of relapse after allogeneic hematopoietic cell transplantation (allo-HCT) in patients with advanced-stage multiple myeloma (MM). In this study, we evaluated efficacy RIT combination chemotherapy-based reduced-intensity conditioning (RIC). was based on coupling an anti-CD66 antibody beta emitter 188-rhenium (188-re) for targeted bone marrow irradiation. Between 2012 and 2018, 30 MM, most them heavily pretreated various therapies...
Study Design Mutlidisciplinary consensus recommendations for patients suffering from multiple myeloma (MM) involvement of the spinal column by Spine Section German Association Orthopaedic and Trauma Surgeons. Objective To provide a comprehensive multidisciplinary diagnostic therapeutic approach to summarize current literature on management pathological thoracolumbar vertebral fractures in with myeloma. Methods Multidisciplinary using classical process provided radiation oncologists, medical...
Abstract Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes into non-toxic metabolites. The recommended dose of glucarpidase 50 U/kg, which never formally established finding study humans. Few case reports, mostly children, suggest lower doses might be equally effective lowering levels. Methods Seven patients toxic plasma...